The usefulness of mutational data on prognosis of myelodysplastic syndromes: alone or incorporated into the IPSS-R?
作者信息
Li Bing, Liu Jinqin, Xu Zefeng, Qin Tiejun, Shi Zhongxun, Song Zhen, Huang Huijun, Fang Liwei, Zhang Hongli, Pan Lijuan, Hu Naibo, Qu Shiqiang, Zhang Yue, Huang Gang, Xiao Zhijian
机构信息
MDS and MPN Centre, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
State Key Laboratory of Experimental Haematology, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
出版信息
Br J Haematol. 2018 Dec;183(5):815-819. doi: 10.1111/bjh.15036. Epub 2017 Nov 28.
Abstract
摘要
相似文献
1
The usefulness of mutational data on prognosis of myelodysplastic syndromes: alone or incorporated into the IPSS-R?
Br J Haematol. 2018 Dec;183(5):815-819. doi: 10.1111/bjh.15036. Epub 2017 Nov 28.
2
Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome.
Blood Cancer J. 2018 Apr 4;8(4):39. doi: 10.1038/s41408-018-0074-7.
3
A novel scoring system integrating molecular abnormalities with IPSS-R can improve the risk stratification in patients with MDS.
BMC Cancer. 2021 Feb 6;21(1):134. doi: 10.1186/s12885-021-07864-y.
4
Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.
Eur J Cancer. 2016 Mar;56:10-20. doi: 10.1016/j.ejca.2015.12.004. Epub 2016 Jan 19.
5
Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes.
Leuk Lymphoma. 2019 Jun;60(6):1522-1527. doi: 10.1080/10428194.2018.1542151. Epub 2018 Nov 30.
6
IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients.
Am J Hematol. 2014 Sep;89(9):E142-9. doi: 10.1002/ajh.23765. Epub 2014 Jun 19.
7
Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.
Leukemia. 2016 Nov;30(11):2214-2220. doi: 10.1038/leu.2016.138. Epub 2016 May 20.
8
Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes.
Cancer Sci. 2020 Feb;111(2):580-591. doi: 10.1111/cas.14270. Epub 2019 Dec 24.
9
Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes.
Ann Hematol. 2016 Oct;95(11):1795-804. doi: 10.1007/s00277-016-2759-y. Epub 2016 Aug 17.
10
Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).
Oncotarget. 2016 Sep 27;7(39):63177-63188. doi: 10.18632/oncotarget.11050.
引用本文的文献
1
deletion as an MRD-dependent risk factor in childhood B-ALL: A post hoc analysis from a prospective cohort.
Hemasphere. 2025 Mar 31;9(4):e70115. doi: 10.1002/hem3.70115. eCollection 2025 Apr.
2
[Sternal bone marrow cell morphology evaluation utility for diagnostic categorization in patients with acquired hypocellular bone marrow failure syndromes].
Zhonghua Xue Ye Xue Za Zhi. 2022 Nov 14;43(11):928-933. doi: 10.3760/cma.j.issn.0253-2727.2022.11.008.
3
[Prognostic factors of cyclosporine A combined with danazol with or without thalidomide in myelodysplastic syndrome treatment with low-percentage bone marrow blasts].
Zhonghua Xue Ye Xue Za Zhi. 2021 May 14;42(5):376-382. doi: 10.3760/cma.j.issn.0253-2727.2021.05.005.
4
Concurrence of Myelodysplastic syndromes and large granular lymphocyte leukemia: clinicopathological features, mutational profile and gene ontology analysis in a single center.
Am J Cancer Res. 2021 Apr 15;11(4):1616-1631. eCollection 2021.
5
Integration Analysis of or Mutation With Bone Marrow Blast Can Improve Risk Stratification in the Patients With Lower Risk Myelodysplastic Syndrome.
Front Oncol. 2021 Jan 13;10:610525. doi: 10.3389/fonc.2020.610525. eCollection 2020.
6
[Genetic characteristics and prognostic values of RAS mutations in patients with myelofibrosis].
Zhonghua Xue Ye Xue Za Zhi. 2020 Dec 14;41(12):989-995. doi: 10.3760/cma.j.issn.0253-2727.2020.12.004.
7
Severe ineffective erythropoiesis discriminates prognosis in myelodysplastic syndromes: analysis based on 776 patients from a single centre.
Blood Cancer J. 2020 Aug 14;10(8):83. doi: 10.1038/s41408-020-00349-4.
8
[Mean corpuscular volume ≤100 fl was an independent prognostic factor in patients with myelodysplastic syndrome and bone marrow blast<5 percent].
Zhonghua Xue Ye Xue Za Zhi. 2020 Jan 14;41(1):28-33. doi: 10.3760/cma.j.issn.0253-2727.2020.01.006.
9
Prognostic impact of red blood cell distribution width in myelodysplastic syndromes.
Br J Haematol. 2019 Jul;186(2):352-355. doi: 10.1111/bjh.15830. Epub 2019 Mar 5.
10
Chromatin regulator Asxl1 loss and Nf1 haploinsufficiency cooperate to accelerate myeloid malignancy.
J Clin Invest. 2018 Dec 3;128(12):5383-5398. doi: 10.1172/JCI121366. Epub 2018 Oct 29.
本文引用的文献
1
Dynamics of clonal evolution in myelodysplastic syndromes.
Nat Genet. 2017 Feb;49(2):204-212. doi: 10.1038/ng.3742. Epub 2016 Dec 19.
2
Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.
Leukemia. 2016 Nov;30(11):2214-2220. doi: 10.1038/leu.2016.138. Epub 2016 May 20.
3
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.
4
Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes.
Nat Commun. 2015 Jan 9;6:5901. doi: 10.1038/ncomms6901.
5
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.
Leukemia. 2014 Feb;28(2):241-7. doi: 10.1038/leu.2013.336. Epub 2013 Nov 13.
6
Clinical and biological implications of driver mutations in myelodysplastic syndromes.
Blood. 2013 Nov 21;122(22):3616-27; quiz 3699. doi: 10.1182/blood-2013-08-518886. Epub 2013 Sep 12.
7
Revised international prognostic scoring system for myelodysplastic syndromes.
Blood. 2012 Sep 20;120(12):2454-65. doi: 10.1182/blood-2012-03-420489. Epub 2012 Jun 27.
8
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.
Cancer. 2008 Sep 15;113(6):1351-61. doi: 10.1002/cncr.23697.
9
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.
J Clin Oncol. 2007 Aug 10;25(23):3503-10. doi: 10.1200/JCO.2006.08.5696.
10
International scoring system for evaluating prognosis in myelodysplastic syndromes.
Blood. 1997 Mar 15;89(6):2079-88.
Zotero 插件